DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and polarizes the immune response towards a Th2 phenotype

Journal of Neuroimmunology

Volumn 205, Issue 1-2, 2008, Pages 57-63

  Movsesyan, Nina ^a,b   Mkrtichyan, Mikayel ^a   Petrushina, Irina ^b   Ross, Ted M ^c   Cribbs, David H ^b,d   Agadjanyan, Michael G ^a,b   Ghochikyan, Anahit ^a  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; AN 1792; DNA vaccine; Immunotherapy; Molecular adjuvant

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; COMPLEMENT COMPONENT C3D; DNA VACCINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; CHO CELLS; COMPLEMENT C3D; CRICETINAE; CRICETULUS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFECTION; VACCINES, DNA;

EID: 56349165547     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2008.08.016     Document Type: Article

References (52)

1. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174 (2005) 1580-1586
2. Ahearn J.M., Fischer M.B., Croix D., Goerg S., Ma M., Xia J., et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 4 (1996) 251-262
3. Boche D., DeBeer S., Cox A., Wilkinson D., Holmes C., Neal J., et al. Evidence of a Transient Increase in Cerebral Amyloid Angiopathy After Abeta42. Immunization in Human Alzheimer's Disease, 8th International Conference "Alzheimer's and Parkinson's Disease: Progress and New Perspectives", Salzburg, Austria (2007)
4. Carroll M.C. The role of complement and complement receptors in induction and regulation of immunity. Annu. Rev. Immunol. 16 (1998) 545-568
5. Carter R.H., and Fearon D.T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256 (1992) 105-107
6. Chen G., Chen K.S., Kobayashi D., Barbour R., Motter R., Games D., et al. Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J. Neurosci. 27 (2007) 2654-2662
7. Cherukuri A., Cheng P.C., and Pierce S.K. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J. Immunol. 167 (2001) 163-172
8. Cherukuri A., Cheng P.C., Sohn H.W., and Pierce S.K. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 14 (2001) 169-179
9. Cribbs D.H., and Agadjanyan M.G. Immunotherapy for Alzheimer's disease: potential problems and possible solutions. Curr. Immunol. Rev. 1 (2005) 139-155
10. Cribbs D.H., Ghochikyan A., Tran M., Vasilevko V., Petrushina I., Sadzikava N., et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int. Immunol. 15 (2003) 505-514
11. Croix D.A., Ahearn J.M., Rosengard A.M., Han S., Kelsoe G., Ma M., et al. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 183 (1996) 1857-1864
12. de Jong D., Jansen R.W., Kremer B.P., and Verbeek M.M. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J. Gerontol. A. Biol. Sci. Med. Sci. 61 (2006) 755-758
13. Dempsey P.W., Allison M.E., Akkaraju S., Goodnow C.C., and Fearon D.T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271 (1996) 348-350
14. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., and Holtzman D.M. Cerebrospinal Fluid Biomarkers of Early Stage Alzheimer Disease, 8th International Conference "Alzheimer's and Parkinson's Disease: Progress and New Perspectives", Salzburg, Austria (2007)
15. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., and Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64 (2007) 343-349
16. Fearon D.T. Innate immunity - beginning to fulfill its promise?. Nat. Immunol. 1 (2000) 102-103
17. Ferrer I., Rovira M.B., Guerra M.L.S., Rey M.J., and Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14 (2004) 11-20
18. Finkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu. Rev. Immunol. 8 (1990) 303-333
19. Gessner A., Blum H., and Rollinghoff M. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice. Immunobiology 189 (1993) 419-435
20. Ghochikyan A., Vasilevko V., Petrushina I., Tran M., Sadzikava N., Babikyan D., et al. Generation and chracterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-interleukin-4 minigene. Eur. J. Immunol. 33 (2003) 3232-3241
21. Ghochikyan A., Mkrtichyan M., Petrushina I., Movsesyan N., Karapetyan A., Cribbs D.H., et al. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 24 (2006) 2275-2282
22. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
23. Green T.D., Montefiori D.C., and Ross T.M. Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J. Virol. 77 (2003) 2046-2055
24. Grubeck-Loebenstein B., and Wick G. The aging of the immune system. Adv. Immunol. 80 (2002) 243-284
25. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
26. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008) 216-223
27. Huang X.R., Holdsworth S.R., and Tipping P.G. Th2 responses induce humorally mediated injury in experimental anti-glomerular basement membrane glomerulonephritis. J. Am. Soc. Nephrol. 8 (1997) 1101-1108
28. Kaya Z., Afanasyeva M., Wang Y., Dohmen K.M., Schlichting J., Tretter T., et al. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nat. Immunol. 2 (2001) 739-745
29. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55 (2004) 306-319
30. Mamikonyan G., Necula M., Mkrtichyan M., Ghochikyan A., Petrushina I., Movsesyan N., et al. Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils, but not the most toxic oligomers. J. Biol. Chem. 282 (2007) 22376-22386
31. Masliah E., Hansen L., Adame A., Crews L., Bard F., Lee C., et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
32. Mitchell J.A., Green T.D., Bright R.A., and Ross T.M. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 21 (2003) 902-914
33. Mongini P.K., Vilensky M.A., Highet P.F., and Inman J.K. The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). J. Immunol. 159 (1997) 3782-3791
34. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P.B., et al. Reducing AD-like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine- a Novel Immunotherapeutic Strategy. PLos ONE 3 (2008) e21-e24
35. Nickolic W.V., Bai Y., Obregon D., Hou H., Mori T., Zeng J., et al. Transcutaneous β-Amyloid Peptide Immunization of Transgenic Alzheimer's Mice Results in Reduced Cerebral β-Amyloid Deposits in the Absence of T cell Infiltration and Microhemorrhage. PNAS Early Edition (2007) 1-8
36. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003) 448-452
37. Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., et al. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 65 (2006) 1040-1048
38. Nitsch R.M., and Hock C. Immunotherapy Against Beta-Amyloid in Alzheimer's Disease, 8th International Conference "Alzheimer's and Parkinson's Disease: Progress and New Perspectives", Salzburg, Austria (2007)
39. Nogaki F., Muso E., Kobayashi I., Kusano H., Shirakawa K., Kamata T., et al. Interleukin 12 induces crescentic glomerular lesions in a high IgA strain of ddY mice, independently of changes in IgA deposition. Nephrol. Dial. Transplant. 15 (2000) 1146-1154
40. Okura Y., Miyakoshi A., Kohyama K., Park I.K., Staufenbiel M., and Matsumoto Y. Nonviral abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9619-9624
41. Orgogozo J.M., Gilman S., Dartigues J.M., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 1 (2003) 46-54
42. Patton R.L., Kalback W.M., Esh C.L., Kokjohn T.A., Van Vickle G.D., Luehrs D.C., et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am. J. Pathol. 169 (2006) 1048-1063
43. Petrushina I., Ghochikyan A., Mktrichyan M., Mamikonyan G., Movsesyan N., Davtyan H., et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric a{beta} species in amyloid precursor protein transgenic mice. J. Neurosci. 27 (2007) 12721-12731
44. Qu B., Rosenberg R.N., Li L., Boyer P.J., and Johnston S.A. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch. Neurol. 61 (2004) 1859-1864
45. Ross T.M., Xu Y., Bright R.A., and Robinson H.L. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. [Comment In: Nat Immunol. 2000 Aug;1(2):102-3 UI: 21205387]. Nat. Immunol. 1 (2000) 127-131
46. Ross T.M., Xu Y., Green T.D., Montefiori D.C., and Robinson H.L. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res. Hum. Retrovir. 17 (2001) 829-835
47. Schenk D. Opinion: amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev., Neurosci. 3 (2002) 824-828
48. Schultz J.G., Salzer U., Mohajeri M.H., Franke D., Heinrich J., Pavlovic J., et al. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. J. Mol. Med. 82 (2004) 706-714
49. St George-Hyslop P.H., and Morris J.C. Will anti-amyloid therapies work for Alzheimer's disease?. Lancet 372 (2008) 180-182
50. Steinberg D. Companies halt first Alzheimer's vaccine trial. Scientist (2002) 22-23
51. Thornton B.P., Vetvicka V., and Ross G.D. Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. J. Immunol. 152 (1994) 1727-1737
52. Tong T., Fan H., Tan Y., Xiao S., Ling J., Chen H., et al. C3d enhanced DNA vaccination induced humoral immune response to glycoprotein C of pseudorabies virus. Biochem. Biophys. Res. Commun. 347 (2006) 845-851